Pharmaceuticals drug candidate molecules

A chemist at a pharmaceutical company is measuring equilibrium constants for reactions in which drug candidate molecules bind to a protein involved in cancer. The drug... 

The development of the biotechnology industry presents new and novel molecules derived from nature. The utilization of these molecules as pharmaceutical products presents an analytical challenge of a magnitude greater than ever confronted. The drug candidate and closely-related molecules have... 

How does green chemistry now relate to pharmaceuticals production A special challenge for manufacturing of pharmaceuticals is the complexity of the molecules, which requires many synthesis steps. For example, an analysis of 128 drug candidates from three major pharma companies showed that, on average, eight steps are required for the synthesis of active... 

Pharmaceutical drug development of small molecules is initially based on the selection of candidate targets - mainly enzymes, receptors or circulating proteins that are currently targeted by 45, 28 and 11% of marketed compounds, respec-... 

These plans envision assembling a portfolio of in-licensed drug candidates for which collective development risk is deemed to be relatively low. The idea is to in-license molecules that either are too specialized (small market potential) for large pharma or are not visible to their radar because they come from places like Eastern Europe. These stories are favorites of professional investors, because rNPVs can be calculated with relatively low development risk on the basis of demonstrated clinical utility and/or pipeline diversity. Examples include Dura Pharmaceuticals, who marketed prescription products that treat infectious and respiratory diseases, and Gilead who marketed antiviral nucleotides discovered in the Czech Republic. 

Among physicochemical properties, the stability of drug candidates is receiving increasing attention. Unfortunately, its evaluation very often requires a lot of experimental time and profiling of many molecules would be nearly impossible without new, computer-aided methods. Any effort useful to facilitate this first part of pharmaceutical investigation is appreciated because it can be converted to a considerable lowering of the research cost. 

---